Results 171 to 180 of about 164,092 (257)

Mass Spectrometry Structural Proteomics Enabled by Limited Proteolysis and Cross‐Linking

Mass Spectrometry Reviews, EarlyView.
ABSTRACT The exploration of protein structure and function stands at the forefront of life science and represents an ever‐expanding focus in the development of proteomics. As mass spectrometry (MS) offers readout of protein conformational changes at both the protein and peptide levels, MS‐based structural proteomics is making significant strides in the
Haiyan Lu, Zexin Zhu, Lauren Fields, Hua Zhang, Lingjun Li   +4 more
wiley   +1 more source

The ubiquitin-proteasome system is an important driver of EBV-associated nasopharyngeal carcinoma progression: a meta-analysis of transcriptomic data. [PDF]

Sci Rep
Ratnawati H, Sanjaya A, Christiandy A, Young LS, Ott S.   +4 more
europepmc   +1 more source

LKB1 Loss Sensitizes Lung Tumor Spheres to Mitomet‐Induced Ferroptosis, and These Effects are Enhanced by mTOR Inhibition

Molecular Carcinogenesis, EarlyView.
ABSTRACT Owing to their robust antioxidant defense mechanisms, cancer stem‐like cells (CSCs) maintain a low level of oxidative stress, which is crucial for preserving stemness and pluripotency. Therefore, agents that either directly generate reactive oxygen species (ROS) or inhibit the antioxidant defense systems can selectively induce oxidative cell ...
Xueqing Liang, Ali Nakhi, Peter I. Dosa, Gunda I. Georg, Fekadu Kassie   +4 more
wiley   +1 more source

Genotype-by-environment interactions shape ubiquitin-proteasome system activity. [PDF]

Genetics
Avery RR, Collins MA, Albert FW.
europepmc   +1 more source

β‐Aminoisobutyric Acid Alleviates Cisplatin‐Induced Muscle Atrophy by Regulating E3 Ubiquitin Ligases, Apoptosis, Amino Acid Metabolism, Autophagy, and Ferroptosis

Medicine Bulletin, EarlyView.
ABSTRACT Background Cisplatin (CIS) is a widely used broad‐spectrum anticancer agent, but its clinical application is often limited by severe adverse effects, including skeletal muscle atrophy, which compromises patients' quality of life and treatment efficacy.
Hao‐Zhe Wang, Wen‐Bi He, Huan Wang, Hao Wang, Wen‐Jun Fang, Meng‐Qian Li, Jiong‐Xing Huang, Fei‐Peng Chen, Hui‐Guo Wang, Lin Zhu, Xiao‐Guang Liu   +10 more
wiley   +1 more source

Dual Targeting of IDH2 and the Ubiquitin-Proteasome System Reveals a Functional Vulnerability in Breast Cancer Models. [PDF]

Cancers (Basel)
Gharari N, Mereu E, Luciano B, Heidari B, Mader S, Piva R.   +5 more
europepmc   +1 more source

Dysregulation of the ubiquitin-proteasome system in von Hippel-Lindau syndrome: molecular insights and clinical perspectives. [PDF]

Clin Exp Med
Bi Y, Wang R, Li L, Wang L, Chen X, Nie X, Meng J, Cai S.   +7 more
europepmc   +1 more source

A poliubiquitin receptorok fejlődésstádium-specifikus szabályozása Drosophila melanogasterben [PDF]

, 2009
Lipinszki Zoltán
core  

CRISPR‐Cas9 Genome‐Wide Screening in Paediatric Cancer: Functional Genomics for Target Discovery and the Improvement of Existing Therapies

Medicinal Research Reviews, EarlyView.
ABSTRACT CRISPR‐Cas9 genome‐wide screening has been instrumental towards identifying novel targets for drug discovery in cancer research. However, much of this research has centred specifically on adult cancers, with paediatric cancers being underserviced by current research and screening.
Steven He, Patrick Connerty, Antoine de Weck   +2 more
wiley   +1 more source

Harnessing Ubiquitin-Proteasome System-Related Genes to Identify Subtypes of Bladder Cancer and Reveal Immune Landscape. [PDF]

Am J Mens Health
Shi G, Zhou X, Yang F, Wang T.
europepmc   +1 more source